A detailed history of Morgan Stanley transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 741,514 shares of ALNY stock, worth $211 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
741,514
Previous 675,281 9.81%
Holding current value
$211 Million
Previous $101 Million 78.54%
% of portfolio
0.01%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Oct 17, 2024

BUY
$143.31 - $247.0 $9.49 Million - $16.4 Million
66,233 Added 9.81%
741,514 $180 Million
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $9.49 Million - $16.4 Million
66,233 Added 9.81%
741,514 $180 Million
Q1 2024

Oct 17, 2024

SELL
$146.51 - $198.2 $9.7 Million - $13.1 Million
-66,233 Reduced 8.93%
675,281 $101 Million
Q1 2024

Aug 16, 2024

SELL
$146.51 - $198.2 $19.2 Million - $26 Million
-131,314 Reduced 16.28%
675,281 $101 Million
Q1 2024

May 15, 2024

SELL
$146.51 - $198.2 $19.2 Million - $26 Million
-131,314 Reduced 16.28%
675,281 $101 Million
Q4 2023

Aug 16, 2024

BUY
$151.41 - $196.57 $9.85 Million - $12.8 Million
65,081 Added 8.78%
806,595 $154 Million
Q4 2023

Feb 13, 2024

SELL
$151.41 - $196.57 $61 Million - $79.2 Million
-402,788 Reduced 33.31%
806,595 $154 Million
Q3 2023

Nov 15, 2023

SELL
$170.77 - $211.65 $115 Million - $142 Million
-671,423 Reduced 35.7%
1,209,383 $214 Million
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $120 Million - $138 Million
649,991 Added 52.81%
1,880,806 $357 Million
Q1 2023

May 15, 2023

SELL
$182.66 - $235.53 $29.2 Million - $37.6 Million
-159,825 Reduced 11.49%
1,230,815 $247 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $20.1 Million - $26.1 Million
-108,119 Reduced 7.21%
1,390,640 $330 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $51.3 Million - $85.9 Million
370,144 Added 32.8%
1,498,759 $300 Million
Q2 2022

Oct 27, 2022

BUY
$120.42 - $169.29 $33.7 Million - $47.4 Million
279,958 Added 32.99%
1,128,615 $165 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $33.7 Million - $47.4 Million
279,958 Added 32.99%
1,128,615 $165 Million
Q1 2022

Oct 27, 2022

SELL
$127.18 - $173.91 $35.6 Million - $48.7 Million
-279,958 Reduced 24.81%
848,657 $139 Million
Q1 2022

May 13, 2022

SELL
$127.18 - $173.91 $27.6 Million - $37.7 Million
-217,032 Reduced 20.37%
848,657 $139 Million
Q4 2021

Feb 14, 2022

SELL
$159.56 - $209.29 $130 Million - $171 Million
-815,190 Reduced 43.34%
1,065,689 $181 Million
Q3 2021

Nov 15, 2021

BUY
$169.75 - $207.73 $319 Million - $391 Million
1,880,879 New
1,880,879 $355 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $35B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.